SYBX Prakiraan wutah bathi kanggo taun ngarep synlogictx.com

Lambang korporat lan logo Synlogic Corp (SYBX)

The forward earnings per share growth forecast demonstrates stagnation as Synlogic, Inc. (SYBX) optimizes expenses and licenses technologies to preserve liquidity. Synthesis robotization and AI screening are reducing manual labor, while microbiome reprogramming creates unique "living medicines." The 0.00 metric confirms the current level, signaling a freeze in analyst expectations regarding the company's future revenues.

Synlogic Corp (SYBX): Prakiraan wutah bathi resik saben saham ing taun ngarep saka 04.07.2022 nganti 24.01.2026
Produk dadi Synlogic Inc.

For Synlogic, Inc. (SYBX), whose synthetic biopharmaceutical patents protect R&D investments, the expected EPS growth rate for the coming year serves as an indicator of technology commercialization. This metric is calculated as the percentage ratio of projected earnings per share to the current value, reflecting the expert consensus on business growth rates. A positive trend in this indicator confirms capital stability and the absence of critical leverage during the development phase.

Analisis perusahaan pesaing

ASND (Ascendis Pharma Inc.) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep Madrigal Corp|Prakiraan wutah bathi kanggo taun ngarep CORT|Prakiraan wutah bathi resik saben saham kanggo taun ngarep RYTM (rhythmtx.com)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Akero AKRO|Metsera, Inc. (MTSR) - Prakiraan wutah bathi resik saben saham ing taun ngarep|MLTX - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|CRNX: Prakiraan wutah bathi resik saben saham kanggo taun ngarep|NAMS: Prakiraan wutah bathi kanggo taun ngarep|SLNO - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Amicus Therapeutics, Inc.|89bio Inc (ETNB) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Agios Pharmaceuticals Inc (AGIO)|Prakiraan wutah bathi saben saham kanggo taun ngarep Structure Corp GPCR|Prakiraan wutah bathi resik saben saham kanggo taun ngarep MiMedx Group, Inc. MDXG|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep rezolutebio.com (RZLT)|LXRX: Prakiraan wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep MBX Biosciences, Inc.|Altimmune Corp (ALT) - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep AARD|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Sagimet Biosciences|Prakiraan wutah bathi resik saben saham kanggo taun ngarep BIOA|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Biomea Fusion (BMEA)|QNCX - Prakiraan wutah bathi resik saben saham ing taun ngarep|Prakiraan wutah bathi kanggo taun ngarep GUTS (Fractyl)|Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep vTv Therapeutics, Inc.|Agape ATP Corp. - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Pluri Inc. PLUR|LPCN: Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi saben saham kanggo taun ngarep Matinas BioPharma Holdings|Prakiraan wutah bathi saben saham kanggo taun ngarep SPRB|GLTO: Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi kanggo taun ngarep CTCX|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep lumos-pharma.com|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Organovo ONVO|RDUS: Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep